• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于靶向 B7H6 的人源 scFv 开发独特的细胞毒性嵌合抗原受体。

Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.

机构信息

Thayer School of Engineering, Dartmouth College, 14 Engineering Dr, Hanover, NH 03755, USA.

Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, 1 Medical Center Dr, Lebanon, NH 03756, USA.

出版信息

Protein Eng Des Sel. 2017 Oct 1;30(10):713-721. doi: 10.1093/protein/gzx051.

DOI:10.1093/protein/gzx051
PMID:29040754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5914360/
Abstract

As a stress-inducible natural killer (NK) cell ligand, B7H6 plays a role in innate tumor immunosurveillance and is a fairly tumor selective marker expressed on a variety of solid and hematologic cancer cells. Here, we describe the isolation and characterization of a new family of single chain fragment variable (scFv) molecules targeting the human B7H6 ligand. Through directed evolution of a yeast surface displayed non-immune human-derived scFv library, eight candidates comprising a single family of clones differing by up to four amino acid mutations and exhibiting nM avidities for soluble B7H6-Ig were isolated. A representative clone re-formatted as an scFv-CH1-Fc molecule demonstrated specific binding to both B7H6-Ig and native membrane-bound B7H6 on tumor cell lines with a binding avidity comparable to the previously characterized B7H6-targeting antibody, TZ47. Furthermore, these clones recognized an epitope distinct from that of TZ47 and the natural NK cell ligand NKp30, and demonstrated specific activity against B7H6-expressing tumor cells when expressed as a chimeric antigen receptor (CAR) in T cells.

摘要

作为一种应激诱导的自然杀伤 (NK) 细胞配体,B7H6 在先天肿瘤免疫监视中发挥作用,是一种在多种实体瘤和血液系统恶性肿瘤细胞上表达的相当肿瘤选择性标志物。在这里,我们描述了一种针对人 B7H6 配体的新型单链片段可变 (scFv) 分子的分离和鉴定。通过对酵母表面展示的非免疫人源 scFv 文库进行定向进化,分离到了 8 个候选 scFv 克隆,它们属于一个家族,彼此之间的差异最多可达 4 个氨基酸突变,对可溶性 B7H6-Ig 的亲和力达到纳摩尔级。代表性的 scFv-CH1-Fc 分子重构成 scFv-CH1-Fc 分子,可特异性结合肿瘤细胞系上的 B7H6-Ig 和天然膜结合的 B7H6,其结合亲和力与先前鉴定的 B7H6 靶向抗体 TZ47 相当。此外,这些克隆识别与 TZ47 和天然 NK 细胞配体 NKp30 不同的表位,当在 T 细胞中作为嵌合抗原受体 (CAR) 表达时,对表达 B7H6 的肿瘤细胞具有特异性活性。

相似文献

1
Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.基于靶向 B7H6 的人源 scFv 开发独特的细胞毒性嵌合抗原受体。
Protein Eng Des Sel. 2017 Oct 1;30(10):713-721. doi: 10.1093/protein/gzx051.
2
Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30.基于天然配体的 CAR 工程:应激受体 NKp30 的定向进化。
Cancer Immunol Immunother. 2022 Jan;71(1):165-176. doi: 10.1007/s00262-021-02971-y. Epub 2021 May 27.
3
Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression.嵌合抗原受体与人源 scFv 优先诱导针对高表达 B7H6 的肿瘤的 T 细胞抗肿瘤活性。
Cancer Immunol Immunother. 2018 May;67(5):749-759. doi: 10.1007/s00262-018-2124-1. Epub 2018 Feb 16.
4
B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells.源自B7H6的肽触发淋巴细胞NK92-MI细胞的肿瘤坏死因子-α依赖性免疫刺激活性。
Biopolymers. 2016 Sep;106(5):658-72. doi: 10.1002/bip.22879.
5
B7H6 is a functional ligand for NKp30 in rat and cattle and determines NKp30 reactivity toward human cancer cell lines.B7H6 是大鼠和牛 NKp30 的功能性配体,决定了 NKp30 对人癌细胞系的反应性。
Eur J Immunol. 2019 Jan;49(1):54-65. doi: 10.1002/eji.201847746. Epub 2018 Dec 13.
6
Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.自然细胞毒性受体NKp30的肿瘤细胞配体B7-H6与一种抑制性抗体复合物的表达、结晶及X射线衍射分析
Acta Crystallogr F Struct Biol Commun. 2015 Jun;71(Pt 6):697-701. doi: 10.1107/S2053230X15006755. Epub 2015 May 20.
7
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance.免疫球蛋白超家族配体 B7H6 使 T 细胞应答受 NK 细胞监视。
Sci Immunol. 2024 May 3;9(95):eadj7970. doi: 10.1126/sciimmunol.adj7970.
8
B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.B7H6特异性嵌合抗原受体可导致肿瘤消除和宿主抗肿瘤免疫。
Gene Ther. 2015 Aug;22(8):675-84. doi: 10.1038/gt.2015.29. Epub 2015 Apr 1.
9
Characterization of B7H6, an endogenous ligand for the NK cell activating receptor NKp30, reveals the identity of two different soluble isoforms during normal human pregnancy.NK细胞活化受体NKp30的内源性配体B7H6的特性分析揭示了正常人类妊娠期间两种不同可溶性同种型的身份。
Immunobiology. 2018 Jan;223(1):57-63. doi: 10.1016/j.imbio.2017.10.012. Epub 2017 Oct 6.
10
HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.与NKp30或NKp80结合的HER2特异性免疫配体可触发NK细胞介导的肿瘤细胞裂解,并增强抗体依赖性细胞介导的细胞毒性。
Oncotarget. 2015 Oct 13;6(31):32075-88. doi: 10.18632/oncotarget.5135.

引用本文的文献

1
CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma.CRISPR/Cas9 编辑的TCR的NKp30嵌合抗原受体T细胞对表达B7H6的白血病和黑色素瘤具有卓越的抗肿瘤免疫力。
Int J Mol Sci. 2025 Aug 25;26(17):8235. doi: 10.3390/ijms26178235.
2
Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies.利用 B7-H6 进行抗癌免疫治疗:表达、途径和治疗策略。
Int J Mol Sci. 2024 Sep 25;25(19):10326. doi: 10.3390/ijms251910326.
3
Toward high-throughput engineering techniques for improving CAR intracellular signaling domains.迈向用于改进嵌合抗原受体(CAR)细胞内信号结构域的高通量工程技术。
Front Bioeng Biotechnol. 2023 Mar 27;11:1101122. doi: 10.3389/fbioe.2023.1101122. eCollection 2023.
4
A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors.一种新型靶向 B7-H6 的 IgG 样 T 细胞结合抗体,用于治疗胃肠道肿瘤。
Clin Cancer Res. 2022 Dec 1;28(23):5190-5201. doi: 10.1158/1078-0432.CCR-22-2108.
5
Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.免疫治疗靶向激活自然杀伤细胞受体及其配体在癌症中的作用。
Clin Exp Immunol. 2022 Jul 22;209(1):22-32. doi: 10.1093/cei/uxac028.
6
Tumor Marker B7-H6 Bound to the Coiled Coil Peptide-Polymer Conjugate Enables Targeted Therapy by Activating Human Natural Killer Cells.与卷曲螺旋肽-聚合物缀合物结合的肿瘤标志物B7-H6通过激活人类自然杀伤细胞实现靶向治疗。
Biomedicines. 2021 Nov 2;9(11):1597. doi: 10.3390/biomedicines9111597.
7
Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30.基于天然配体的 CAR 工程:应激受体 NKp30 的定向进化。
Cancer Immunol Immunother. 2022 Jan;71(1):165-176. doi: 10.1007/s00262-021-02971-y. Epub 2021 May 27.
8
Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.超越程序性死亡配体 1:B7-H6 成为小细胞肺癌潜在免疫治疗靶点。
J Thorac Oncol. 2021 Jul;16(7):1211-1223. doi: 10.1016/j.jtho.2021.03.011. Epub 2021 Apr 8.
9
Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.工程化嵌合自然杀伤细胞受体以开发癌症的精准过继免疫疗法。
Clin Exp Immunol. 2020 Oct;202(1):11-27. doi: 10.1111/cei.13478. Epub 2020 Jul 25.
10
Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.寻找 CAR 的钥匙:鉴定用于 T 细胞重定向免疫疗法的新型靶标抗原。
Int J Mol Sci. 2020 Jan 14;21(2):515. doi: 10.3390/ijms21020515.

本文引用的文献

1
Hepatitis B viral replication influences the expression of natural killer cell ligands.乙型肝炎病毒复制影响自然杀伤细胞配体的表达。
Ann Gastroenterol. 2016 Jul-Sep;29(3):348-57. doi: 10.20524/aog.2016.0036. Epub 2016 Apr 25.
2
High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.高亲和力的FRβ特异性嵌合抗原受体T细胞可根除急性髓系白血病和正常髓系谱系细胞,且无造血干细胞毒性。
Leukemia. 2016 Jun;30(6):1355-64. doi: 10.1038/leu.2016.35. Epub 2016 Feb 22.
3
Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production.第2组固有淋巴细胞表达功能性NKp30受体,诱导2型细胞因子产生。
J Immunol. 2016 Jan 1;196(1):45-54. doi: 10.4049/jimmunol.1501102. Epub 2015 Nov 18.
4
Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.肿瘤治疗药物作为应激诱导剂,通过上调NKp30配体B7-H6来增强肿瘤对自然杀伤(NK)细胞溶解作用的敏感性。
J Biol Chem. 2015 Dec 11;290(50):29964-73. doi: 10.1074/jbc.M115.674010. Epub 2015 Oct 15.
5
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.亲和力优化的ErbB2或EGFR嵌合抗原受体T细胞对小鼠肿瘤的治疗指数有所提高。
Cancer Res. 2015 Sep 1;75(17):3596-607. doi: 10.1158/0008-5472.CAN-15-0159.
6
Antibody humanization by structure-based computational protein design.基于结构的计算蛋白质设计实现抗体人源化。
MAbs. 2015;7(6):1045-57. doi: 10.1080/19420862.2015.1076600. Epub 2015 Aug 7.
7
NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.NKP30与B7-H6相互作用通过上调白细胞介素-32表达加重乙型肝炎病毒相关性慢加急性肝衰竭中的肝细胞损伤。
PLoS One. 2015 Aug 4;10(8):e0134568. doi: 10.1371/journal.pone.0134568. eCollection 2015.
8
B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.B7H6特异性双特异性T细胞衔接器可导致肿瘤消除和宿主抗肿瘤免疫。
J Immunol. 2015 Jun 1;194(11):5305-11. doi: 10.4049/jimmunol.1402517. Epub 2015 Apr 24.
9
B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.B7H6特异性嵌合抗原受体可导致肿瘤消除和宿主抗肿瘤免疫。
Gene Ther. 2015 Aug;22(8):675-84. doi: 10.1038/gt.2015.29. Epub 2015 Apr 1.
10
Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies.酵母展示的HIV-1 SOSIP gp140刺突蛋白的定向进化,以提高其表达水平及对构象抗体的亲和力。
PLoS One. 2015 Feb 17;10(2):e0117227. doi: 10.1371/journal.pone.0117227. eCollection 2015.